What's Happening?
Agendia, Inc. has announced that the Swiss Federal Office of Public Health (FOPH) has granted mandatory health insurance coverage for MammaPrint, a multigene expression test used in early-stage breast cancer treatment. Effective July 1, 2026, this decision
follows a comprehensive Health Technology Assessment and formal recommendation from the Federal Commission for General Benefits and Policy Issues. The ruling ensures that eligible patients with estrogen receptor-positive and HER2-negative breast cancer can access MammaPrint tests, which aid in chemotherapy decision-making. This regulatory update solidifies the test's status as a mandatory insurance obligation in Switzerland.
Why It's Important?
The definitive ruling by the Swiss FOPH marks a significant advancement in precision oncology, ensuring that breast cancer patients in Switzerland can benefit from personalized treatment plans based on their tumor biology. By mandating insurance coverage for MammaPrint, the Swiss healthcare system supports the use of genomic assays to prevent overtreatment and protect patients from disease recurrence. This decision could influence other countries to adopt similar measures, promoting the integration of precision medicine into standard cancer care and potentially improving patient outcomes globally.
